STAAR Surgical (NASDAQ:STAA) Given Average Rating of “Hold” by Brokerages

STAAR Surgical (NASDAQ:STAA) has earned an average rating of “Hold” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $42.83.

Several research analysts have weighed in on the company. Canaccord Genuity Group lowered their price target on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a research report on Monday. Stephens upgraded shares of STAAR Surgical to a “hold” rating in a report on Monday, December 2nd. Stifel Nicolaus cut their price target on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, August 26th. Finally, Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, October 31st.

STAAR Surgical Trading Down 4.5 %

Shares of STAA opened at $25.25 on Thursday. STAAR Surgical has a 12 month low of $25.04 and a 12 month high of $52.68. The firm has a fifty day simple moving average of $29.28 and a 200 day simple moving average of $35.19. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of 57.39 and a beta of 0.59.

Institutional Investors Weigh In On STAAR Surgical

A number of hedge funds and other institutional investors have recently modified their holdings of STAA. Arcadia Investment Management Corp MI bought a new stake in shares of STAAR Surgical during the third quarter worth about $37,000. Quarry LP acquired a new stake in STAAR Surgical in the third quarter valued at approximately $50,000. Canada Pension Plan Investment Board bought a new stake in shares of STAAR Surgical during the second quarter worth about $129,000. Larson Financial Group LLC purchased a new position in shares of STAAR Surgical during the second quarter valued at approximately $130,000. Finally, Quest Partners LLC bought a new stake in STAAR Surgical in the 3rd quarter worth about $128,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.